Regulus Therapeutics (RGLS) Hits New 1-Year Low at $1.75

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.75 and last traded at $1.77, with a volume of 1519 shares. The stock had previously closed at $1.88.

A number of brokerages have recently issued reports on RGLS. Wedbush reiterated a “hold” rating and set a $2.00 target price on shares of Regulus Therapeutics in a report on Tuesday, October 9th. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Saturday, October 13th. Wells Fargo & Co decreased their price target on Regulus Therapeutics from $1.50 to $1.00 and set a “market perform” rating for the company in a report on Friday, July 6th. ValuEngine cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 2nd. Finally, B. Riley decreased their price target on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating for the company in a report on Friday, July 6th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $1.42.

The firm has a market capitalization of $16.41 million, a price-to-earnings ratio of -0.15 and a beta of 1.38.



Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%. On average, equities research analysts anticipate that Regulus Therapeutics Inc will post -5 earnings per share for the current year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. A.R.T. Advisors LLC acquired a new position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned approximately 0.16% of Regulus Therapeutics as of its most recent SEC filing.

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Recommended Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply